LOGIN  |  REGISTER
Amneal Pharmaceuticals
Viking Therapeutics

The Oncology Institute Announces Third Quarter 2023 Earnings Release Date and Conference Call

October 18, 2023 | Last Trade: US$3.73 0.06 1.63

CERRITOS, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2023 financial results after the market close on Wednesday, November 8, 2023, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13741314. The replay will be available until November 15, 2023.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.

About The Oncology Institute

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 800 teammates in over 65 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Investors

Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page